Siddhartha Yadav, MD, discusses real-world data demonstrating the mass underutilization of BRCA testing in patients with breast cancer.
At San Antonio Breast Cancer Symposium 2023, Siddhartha Yadav, MBBS, MD, of the Mayo Clinic, presented findings from a real world studying analyzing the utilization of BRCA testing and PARP inhibitors in HER2-negative metastatic breast cancer. Among the notable takeaways of his research, Siddhartha emphasized data revealing that the vast majority of patients go without germline BRCA testing.
Transcript
This transcript has been lightly edited.
Can you provide an overview of the use of BRCA testing and PARP inhibitors in HER2-negative metastatic breast cancer in the context of your study?
The NCCN [National Comprehensive Cancer Network] guidelines, and many national guidelines, recommend that we perform germline testing in patients with HER2-negative metastatic breast cancer so that we can offer PARP inhibitors for treatment. However, we have very limited data from real world settings. So, this was a study that we wanted to look into and see what happens in the real world. Even though all patients with HER2-negative metastatic breast cancer should undergo a germline BRCA testing, is that happening and what are rates? And so we utilized the US real-world data set from Flatiron [Health] to look into this. And Flatiron basically collects data from electronic medical records across different, several 100 clinical sites in the US. And what was surprising was that we found that less than 40%—so if you look at the entire data set—almost approximately 30% to 40% of patients with LG negative metastatic breast cancer underwent germline BRCA testing, which means that 60% to 70% of those patients who should have undergone testing did not undergo testing. So that's kind of the surprising finding of this study.
What are the clinical implications of your findings?
Yeah, so you know, if we think from an implications perspective, first and foremost, while it is surprising. There are other datasets that have also shown that there is clearly under testing of individuals for germline BRCA mutation in metastatic breast cancer. What this means is that there is a subset of patients who, because they have not been tested, would not be eligible for treatment with PARP inhibitors and are currently being undertreated. So, obviously, this is a huge challenge in the field because metastatic breast cancer is a highly lethal malignancy; there are limited treatment options. But if we don't even do testing to identify what treatment options patients would be eligible for, then obviously that does not help them either. So the implications are more so in terms of understanding where there are gaps in testing, and what can we do from a system perspective to improve these germline BRCA testing aids.
Diagnostic Oversights Limit Luspatercept Benefits in MDS
May 8th 2024Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More